Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1809 results
October 2019
-
Story People and Culture
Oncology Careers: Life Changing Purpose
-
Media Release
AveXis presents updated STRONG data at WMS
Older patients (≥ 2 years and < 5 years) achieved a mean increase of 5.9 points from baseline in HFMSE scores, nearly double the clinically meaningful threshold (at a mean duration of follow-up… -
Story Discovery
Women in Science: Lauren Abrey
Learn about the career of our Global Medical Affairs Head for Solid Tumors and Rare Diseases.
-
Key Release
Novartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing entire axSpA spectrum
Phase III PREVENT study met 52-week primary endpoint of ASAS40, showing a sustained response in patients with non-radiographic axial spondyloarthritis (nr-axSpA)[1] Novartis plans FDA submission… -
Media Release
Novartis and Microsoft announce collaboration to transform medicine with artificial intelligence
Multiyear alliance underpins the Novartis commitment to leverage data & Artificial Intelligence (AI) to transform how medicines are discovered, developed and commercializedNovartis to establish…
September 2019
-
Story Discovery
Word on the Street: What is cell and gene therapy?
We leave the lab to find out what people know about cell and gene therapy.
-
Media Release
Novartis announces positive results from Phase III PALLADIUM study of inhaled combination QMF149 in patients with uncontrolled asthma
Once-daily QMF149 demonstrated superior improvement in lung function versus mometasone furoate, meeting primary endpoint[1] PALLADIUM is part of Phase III PLATINUM clinical development program,… -
Media Release
Novartis announces positive results from Phase III IRIDIUM study of inhaled combination QVM149 in patients with uncontrolled asthma
Once-daily QVM149 demonstrated statistically significant improvement in lung function versus QMF149, meeting primary endpoint[1],[2] IRIDIUM is largest study in Phase III PLATINUM clinical… -
Key Release
Novartis Kisqali® delivers consistently superior overall survival – MONALEESA-3 trial demonstrates more life for postmenopausal HR+/HER2- advanced breast cancer patients
In MONALEESA-3, Kisqali plus fulvestrant achieved statistically significant overall survival benefit vs. fulvestrant alone in postmenopausal women (HR=0.724; p=0.00455)[1] Kisqali is the only… -
Featured News
European Patient Innovation Summit recommends increasing the impact of digital technologies
European Patient Innovation Summit publishes a position paper on Digital Health from a Patient Perspective with recommendations on digital health.
-
Story From Our Labs
Seeing through knees in quest to alleviate osteoarthritis
Novartis researchers are peering deep inside knees to see if regenerated cartilage is springy like natural cartilage.
-
Statement
AveXis data integrity - updates
Form 483 posting by US Food and Drug Administration (FDA) – Novartis statement